Structure-based discovery of potent CARM1 inhibitors for colorectal cancer therapy

Eur J Med Chem. 2024 Apr 5:269:116288. doi: 10.1016/j.ejmech.2024.116288. Epub 2024 Mar 4.

Abstract

Coactivator-associated arginine methyltransferase 1 (CARM1) plays an important role in cell proliferation and gene expression, and is highly expressed in a variety of tumor tissues. Guided by our previous reported structure of DCPR049_12, we focused on designing and evaluating selective CARM1 inhibitors, resulting in the identification of compound 11f as a promising lead candidate. Compound 11f displayed potent inhibition of CARM1 (IC50 = 9 nM). Comprehensive evaluations, including in vitro metabolic stability assessments, molecular modelling, cellular studies, and in vivo anti-tumor studies, confirmed that it induced cancer cell apoptosis and specifically inhibited CARM1's methylation function. Notably, compound 11f displayed significant anti-proliferative effects on colorectal cancer cell lines, showcasing its potential for targeted therapies against CARM1-related diseases. This study provides valuable insights for the future development of specific and effective CARM1 inhibitors.

Keywords: Antitumor; Arginine methyltransferase; Inhibitor; Methylate; PRMTs.

MeSH terms

  • Apoptosis
  • Cell Line
  • Colorectal Neoplasms* / drug therapy
  • Humans
  • Protein-Arginine N-Methyltransferases*

Substances

  • coactivator-associated arginine methyltransferase 1
  • Protein-Arginine N-Methyltransferases